subscribeSubscribe
Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA

Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA
GLOBENEWSWIRE
06 Mar 2024
Share Share
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA
GLOBENEWSWIRE
30 Jun 2023
Share Share
Alcyone Receives FDA IDE Approval to Clinical Study ThecaFlex DRxTM of SPINRAZA

Alcyone Receives FDA IDE Approval to Clinical Study ThecaFlex DRxTM of SPINRAZA
PR NEWSWIRE
27 Jun 2023
Share Share
Royalty Pharma Acquires Ionis` Royalty In Spinraza, Pelacarsen For $1.1 Bln

Royalty Pharma Acquires Ionis` Royalty In Spinraza, Pelacarsen For $1.1 Bln
PR NEWSWIRE
10 Jan 2023
Share Share
Biogen Plans to start Phase 3b Study of High Dose Nusinersen

Biogen Plans to start Phase 3b Study of High Dose Nusinersen
GLOBENEWSWIRE
15 Sep 2021
Share Share
Biogen to test Spinraza in those who`ve had Roche`s Evrysdi

Biogen to test Spinraza in those who`ve had Roche`s Evrysdi
Eric Sagonowsky FIERCEPHARMA
15 Sep 2021
Share Share
Biogen to Initiate PIIIb for Evaluating potential of Higher Dose of Nusinersen

Biogen to Initiate PIIIb for Evaluating potential of Higher Dose of Nusinersen
BIOSPACE
15 Sep 2021
Share Share
Biogen reports new data backing long-term benefit of Spinraza

Biogen reports new data backing long-term benefit of Spinraza
Lucy Parsons PHARMATIMES
11 Jun 2021
Share Share
Biogen reports new data backing long-term benefit of Spinraza

Biogen reports new data backing long-term benefit of Spinraza
Lucy Parsons PHARMATIMES
11 Jun 2021
Share Share
Biogen reports new data backing long-term benefit of Spinraza

Biogen reports new data backing long-term benefit of Spinraza
Lucy Parsons PHARMATIMES
11 Jun 2021
Share Share